Deutsche Bank AG Has $2.82 Million Stock Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Deutsche Bank AG raised its position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 77.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 142,397 shares of the company's stock after buying an additional 62,083 shares during the period. Deutsche Bank AG owned about 0.20% of Kiniksa Pharmaceuticals worth $2,817,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of KNSA. SG Americas Securities LLC bought a new position in shares of Kiniksa Pharmaceuticals in the fourth quarter valued at about $355,000. Charles Schwab Investment Management Inc. increased its position in Kiniksa Pharmaceuticals by 36.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 122,019 shares of the company's stock valued at $2,414,000 after acquiring an additional 32,393 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in Kiniksa Pharmaceuticals in the 4th quarter valued at about $3,955,000. Globeflex Capital L P raised its stake in shares of Kiniksa Pharmaceuticals by 217.1% in the fourth quarter. Globeflex Capital L P now owns 88,596 shares of the company's stock worth $1,752,000 after acquiring an additional 60,656 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in shares of Kiniksa Pharmaceuticals by 3.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 771,607 shares of the company's stock worth $15,262,000 after purchasing an additional 29,300 shares in the last quarter. Institutional investors own 53.95% of the company's stock.

Analyst Ratings Changes

A number of analysts recently weighed in on KNSA shares. Wedbush reissued an "outperform" rating and issued a $34.00 price target on shares of Kiniksa Pharmaceuticals in a report on Wednesday, April 16th. Jefferies Financial Group increased their price objective on Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the company a "buy" rating in a research report on Tuesday, April 29th. Finally, Citigroup started coverage on Kiniksa Pharmaceuticals in a research report on Thursday, March 13th. They set a "buy" rating and a $40.00 target price for the company. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $38.80.

Kiniksa Pharmaceuticals Trading Down 1.5%

Shares of KNSA traded down $0.40 on Tuesday, reaching $26.49. 646,540 shares of the company's stock were exchanged, compared to its average volume of 488,962. The business has a 50 day moving average price of $23.38 and a two-hundred day moving average price of $21.54. Kiniksa Pharmaceuticals, Ltd. has a 12 month low of $17.38 and a 12 month high of $28.56. The stock has a market capitalization of $1.93 billion, a P/E ratio of -189.20 and a beta of 0.07.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last released its earnings results on Tuesday, April 29th. The company reported $0.11 EPS for the quarter, topping analysts' consensus estimates of $0.02 by $0.09. The firm had revenue of $137.79 million during the quarter, compared to analyst estimates of $128.35 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The business's quarterly revenue was up 72.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.25) EPS. Equities research analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current year.

Insider Transactions at Kiniksa Pharmaceuticals

In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 12,000 shares of the stock in a transaction dated Monday, May 19th. The stock was sold at an average price of $26.41, for a total value of $316,920.00. Following the transaction, the chief operating officer now owns 72,363 shares of the company's stock, valued at approximately $1,911,106.83. This represents a 14.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Mark Ragosa sold 36,372 shares of the business's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $22.25, for a total value of $809,277.00. Following the transaction, the chief financial officer now owns 22,958 shares of the company's stock, valued at $510,815.50. The trade was a 61.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 243,640 shares of company stock worth $5,986,056 in the last three months. Insiders own 54.57% of the company's stock.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.